Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
78447.050.8133%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Xilio Therapeutics Inc

XLONASDAQ
Trade with Public
Trade with Public
$9.00
-0.02-0.22%
At close: Sep 4, 5:00 PM EST
$9.01
0.010.11%
After Hours: Sep 2, 4:34 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Xilio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xilio Therapeutics (XLO).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOutperform# Analysts2Avg. Consensus PT$3Upside to Avg. PT-66.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2025Leerink PartnersDaina GrayboschInitiateOutperform$2
Nov 8, 2024Raymond JamesDane LeonePT CutOutperform$6→$4

Analyst Ratings News

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

Raymond James analyst Dane Leone maintains Xilio Therapeutics (NASDAQ:XLO) with a Outperform and lowers the price target from $6 to $4.
Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $20 to $10.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

Benzinga Insights

PRO
Chardan Capital Initiates Coverage On Xilio Therapeutics with Buy Rating, Announces Price Target of $7

Chardan Capital analyst Matthew Barcus initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved